Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT

G Edan, L Kappos, X Montalbán, C H Polman, M S Freedman, H-P Hartung, D Miller, F Barkhof, J Herrmann, V Lanius, B Stemper, C Pohl, R Sandbrink, D Pleimes, BENEFIT Study Group, G Edan, L Kappos, X Montalbán, C H Polman, M S Freedman, H-P Hartung, D Miller, F Barkhof, J Herrmann, V Lanius, B Stemper, C Pohl, R Sandbrink, D Pleimes, BENEFIT Study Group

Abstract

Objective: To examine the long-term impact of early treatment initiation of interferon beta-1b (IFNB1b, Betaferon/Betaseron) in patients with a first event suggestive of multiple sclerosis (MS).

Methods: In the original placebo-controlled phase of BENEFIT, patients were randomised to IFNB1b 250 μg or placebo subcutaneously every other day. After 2 years or diagnosis of clinically definite MS (CDMS), all patients were offered open-label IFNB1b treatment for a maximum duration of 5 years. Thereafter, patients were enrolled in an observational extension study for up to 8.7 years.

Results: Of the initial 468 patients, 284 (60.7%; IFNB1b: 178 (61.0% of the original arm), placebo: 106 (60.2% of original arm)) were enrolled in the extension study. 94.2% of patients were receiving IFNB1b. Patients originally randomised to IFNB1b had a reduced risk of developing CDMS by 32.2% over the 8-year observation period (HR 0.678; 95% CI 0.525 to 0.875; p=0.0030), a longer median time to CDMS by 1345 days (95% CI 389 to 2301), and a lower annualised relapse rate (0.196 (95% CI 0.176 to 0.218) versus 0.255 (95% CI 0.226 to 0.287), p=0.0012), with differences mainly emerging in the first year of the study. Cognitive outcomes remained higher in the early treated patients. EDSS remained low over time with a median of 1.5 in both arms.

Conclusions: These 8-year results provide further evidence supporting early initiation of treatment with IFNB1b in patients with a first event suggestive of MS.

Keywords: INTERFERON; INTERVENTIONAL; MULTIPLE SCLEROSIS; RANDOMISED TRIALS.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Proportion of patients requiring escalation therapy pooled across total population. The majority of patients did not require escalation therapy during the study. The treatments used by the 6.6% who required escalation therapy are shown in the inset box. Escalation therapies included alemtuzumab, cyclosporine, cladribine, cyclophosphamide, daclizumab, fingolimod, fingolimod hydrochloride, methotrexate, methotrexate sodium, mitoxantrone, mitoxantrone hydrochloride, mycophenolate mofetil, mycophenolate sodium, natalizumab, rituximab, sirolimus, tacrolimus and temsirolimus. aWhen multiple therapies are listed, the order indicates the sequence of therapies. Inset box lists only the escalation therapies administered during the study. Escalation therapy was generally similar between groups, with the exception of natalizumab (early treatment, 10 patients (3.4%); delayed treatment, 9 patients (5.1%)).
Figure 2
Figure 2
Kaplan–Meier estimates for the probability of CDMS over 8 years. Probability of conversion to CDMS was significantly higher in the delayed treatment group. At the 50th percentile, conversion to CDMS was delayed by approximately 3.7 years in the early treatment group. aBy proportional hazards regression, adjusted for steroid use during the first clinical event, type of disease onset, and categorised number of T2 lesions on BENEFIT screening MRI. CDMS, clinically definite multiple sclerosis.
Figure 3
Figure 3
Annualised relapse rate (ARR) by year in the total number of patients observed overall and during each study year. ARR was significantly lower in the early treatment group than in the delayed treatment group over the entire study period as well as in years 1 and 8. ARR was lower among patients in the early treatment than the delayed treatment group for years 1 and 2 (0.233 (95% CI 0.195 to 0.277) vs 0.325 (95% CI 0.268 to 0.392), p=0.0073a; RR=0.705, 95% CI 0.546 to 0.910) and from years 6 to 8 (0.146 (95% CI 0.115 to 0.184)) vs 0.212 (95% CI 0.164 to 0.270); p=0.032a; RR=0.694, 95% CI 0.497 to 0.969). aWald-type χ2 test. Generalised linear Poisson regression model.

References

    1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938–52.
    1. Ebers GC, Reder AT, Traboulsee A, et al. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther 2009;31:1724–36.
    1. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389–97.
    1. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987–97.
    1. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242–9.
    1. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–31.
    1. Hartung HP, Freedman MS, Polman CH, et al. Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology 2011;77:835–43.
    1. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122(pt 5):871–82.
    1. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47:129–39.
    1. EuroQol group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.
    1. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131(pt 3):808–17.
    1. Penner IK, Stemper B, Calabrese P, et al. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler 2012;18:1466–71.
    1. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133(Pt 7):1914–29.
    1. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010;133(Pt 7):1900–13.
    1. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66:678–84.
    1. Kinkel RP, Dontchev M, Kollman C, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012;69:183–90.
    1. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898–904.
    1. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503–11.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅